Surgical perspective in neoadjuvant chemoimmunotherapy for stage <scp>II</scp>–<scp>III</scp> non‐small cell lung cancer

Abstract

In this study, neoadjuvant chemoimmunotherapy was found to reduce tumor volume, cause pathological downstaging, and raise the surgical resection rate of patients with locally advanced NSCLC, and achieve a 100% R0 resection rate. There was an acceptable rate of postoperative complications. Thus, neoadjuvant chemoimmunotherapy is safe and practical.